Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Safety and Efficacy of EMB 001 in Subjects With Moderate-to-Severe Cocaine Use Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Aug 2023
Price :
$35
*
At a glance
- Drugs Metyrapone/oxazepam (Primary)
- Indications Cocaine-related disorders
- Focus Therapeutic Use
- Sponsors Embera NeuroTherapeutics
- 07 Aug 2023 Status changed from recruiting to completed.
- 30 Jun 2021 According to an Embera NeuroTherapeutics media release, about 70 percent of subjects enrolled out of total 80 subjects in the trial. The company expects to present the topline data in Q1 2022.
- 31 Aug 2020 According to an Embera NeuroTherapeutics media release, first patient has been dosed.